Dataset Information

LC-MS/MS-based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1

ABSTRACT: The study is based on the identification of serum protein biomarkers for NT 1. A total of 27 serum samples were collected (16 NT 1 and 11 controls), the altered expression levels of low-abundant proteins (DEPs) associated with narcolepsy type 1 was investigated by comparing the proteomes of the two sample cohorts. DEPs that are revealed to be most related to NT 1 pathogenesis and have high levels of fold changes were further targeted and validated by LC-PRM-MS. Then, the effects of the DEPs were explored by system biology analysis.

INSTRUMENT(S): LTQ Orbitrap Velos, Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

DISEASE(S): Narcolepsy

SUBMITTER: Akeem Sanni

LAB HEAD: Yehia Mechref

PROVIDER: PXD038248 | Pride | 2023-05-10

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 162

Publications

LC-MS/MS-Based Proteomics Approach for the Identification of Candidate Serum Biomarkers in Patients with Narcolepsy Type 1.

Sanni Akeem A Goli Mona M Zhao Jingfu J Wang Junyao J Barsa Chloe C El Hayek Samer S Talih Farid F Lanuzza Bartolo B Kobeissy Firas F Plazzi Giuseppe G Moresco Monica M Mondello Stefania S Ferri Raffaele R Mechref Yehia Y

Biomolecules 20230223 3

Narcolepsy type 1 (NT1) is the most common type of narcolepsy known to be caused by the loss of specific neurons responsible for producing peptide neurotransmitters (orexins/hypocretins), resulting in a sleep-wake cycle disorder. It is characterized by its association with cataplexy and abnormalities in rapid eye movement. To date, no cure has been established for this life-threatening condition. Misdiagnosis of NT1 is also quite common, although it is not exceedingly rare. Therefore, successful ...[more]

PMID: 36979356

Similar Datasets

Project description:To advance understanding of mechanisms leading to biological and transcriptional endpoints related to estrogen action in the mouse uterus, we have mapped ERM-NM-1 and RNA polymerase II binding sites using chromatin immunoprecipitation (ChIP) followed by sequencing of enriched chromatin fragments (ChIP-seq). In the absence of hormone, 5184 ERM-NM-1 binding sites were apparent in the vehicle treated ovariectomized uterine chromatin, while 17240 were seen one hour after estrogen (E2) treatment, indicating that some sites are occupied by unliganded ERM-NM-1, and that ERM-NM-1 binding is increased by E2. Approximately 15% of the uterine ERM-NM-1 binding sites were adjacent to (<10 KB) annotated transcription start sites and many sites are found within genes or are found more than 100 KB distal from mapped genes; however, the density (sites per bp) of ERM-NM-1 binding sites is significantly greater adjacent to promoters. An increase in quantity of sites but no significant positional differences were seen between vehicle and E2 treated samples in the overall locations of ERM-NM-1 binding sites either distal from, adjacent to or within genes. Analysis of the PolII data revealed the presence of poised promoter proximal PolII on some highly upregulated genes. Additionally, co-recruitment of PolII and ERM-NM-1 to some distal enhancer regions was observed. A de novo motif analysis of sequences in the ERM-NM-1 bound chromatin confirmed that estrogen response elements (EREs) were significantly enriched. Interestingly, in areas of ERM-NM-1 binding without predicted ERE motifs, homeodomain transcription factor (Hox) binding motifs were significantly enriched. The integration of the ERM-NM-1 and PolII binding sites from our uterine ChIP-seq data with transcriptional responses revealed in our uterine microarrays has the potential to greatly enhance our understanding of mechanisms governing estrogen response in uterine and other estrogen target tissues. one sample each, vehicle ER-alpha ChIP seq,1 hour estradiol ER-alpha ChIP seq, vehicle RNA polymerase II ChIP seq,1 hour estradiol RNA polymerase II ChIP seq, input DNA

			Action	DRS
	10FF_NT1_PRM.mzid.gz	Mzid
	10FF_PRM_1Ug_7_27_22.mgf	Mgf
	10FF_PRM_1Ug_7_27_22.raw	Raw
	11DSG_NT1_PRM.mzid.gz	Mzid
	11DSG_NTI_PRM_1Ug_7_27_22.mgf	Mgf